We use cookies.

To make your experience the best it can be, we use cookies and similar technologies on our site. We need your permission to allow these technologies, which will maximise browsing experience. For more information on how we use cookies and how to change your cookie settings, please see our cookies and privacy policy.

X
CONTACT US

CONTACT US

Please complete this short form to get in touch with a member of our team and we will get back to you as soon as we can.

Header image for the current page Analysing the impact of COVID-19 vaccinations for patients with multiple sclerosis

Analysing the impact of COVID-19 vaccinations for patients with multiple sclerosis

Share this page

Arden & GEM’s business intelligence team has co-authored an article for the Multiple Sclerosis and Related Disorders Journal following analysis of the risk of COVID-19 infections among MS patients and the impact of vaccination on cohorts taking different treatments.

As the national data processors for directly commissioned services within England, Arden & GEM’s business intelligence service produces a range of analytical reports to support specialised commissioning policy and clinical decision-making for patients with rare and complex conditions.

When the neurology team at Nottingham University Hospitals NHS Trust (NUH) wanted to understand the risk of COVID-19 infection on MS patients taking different immunomodulatory disease-modifying therapies, one of Arden & GEM’s expert analysts was able to help.

By linking national NHS data with the UK Health Security Agency testing data, analytical lead, Sameer Patel, was able to determine if patients on a particular treatment of disease modifying therapy were more likely to be infected based on humoral and cellular immune responses.

Analytical assumptions were reviewed by a panel of clinicians, including a neurologist and pharmacist, with the group publishing their findings and conclusions in an article titled ‘Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England’ in Volume 57 of Multiple Sclerosis and Related Disorders.

Through accessing and analysing national pseudonymised data, rather than smaller acute cohorts, the researchers found that certain medicines were associated with an increased risk of COVID-19 infections following vaccination which has led to changes in prescribing practice both locally and nationally.

The method is now being used as a template for other conditions such as severe asthma and cystic fibrosis, with plans to also replicate the approach with different viruses.

A copy of the published article can be found here.